Abstract
Background: Duvelisib (DUV) is a new oral phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma inhibitor. It has been recently granted an accelerated approval for treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). It is also effective in therapy of T-cell lymphoma, solid tumors, and non-Hodgkin's lymphoma. In literature, there is no method valid for quantitation of DUV in human plasma for its therapeutic monitoring and pharmacokinetic studies.
Purpose: The purpose of this study is the establishment of a highly sensitive HPLC method with fluorescence detection for quantitation of DUV in plasma for its therapeutic monitoring and pharmacokinetic studies of DUV.
Methods: The resolution of DUV and the internal standard (IS) olaparib (OLA) was achieved on Nucleosil CN column, with a mobile phase composed of acetonitrile:water (25:75, v/v) at a flow rate of 1.7 mL min(-1). The fluorescence of both DUV and OLA was detected at 410 nm after excitation at 280 inn. The method was validated according to the guidelines of bioanalytical method validation.
Results: The method was linear in the range of 5-100 ng mL(-1) , and its limit of detection (LOD) and limit of quantitation (LOQ) were 2.12 ng mL(-1) and 7 ng mL(-1), respectively. The precisions of the method were <= 8.26%, and its accuracies were >= 95.32%. All the other validation parameters were satisfactory. The proposed method was successfully employed to the investigation of the pharmacokinetic profile of DUV in rats following a 25 mg/kg single dose of oral administration.
Conclusion: The method is characterized with high sensitivity, accuracy, simple sample pretreatment, rapidity, eco-friendly as it consumes low volumes of organic solvent in the mobile phase and has high analysis throughput as its run time was short (similar to 10 min).